Navigation Links
Molecular Diagnostics Role in Cancer Testing Analyzed in In-demand TriMark Report Published at

London, UK (PRWEB) January 06, 2014

Nowadays, molecular diagnostics (MD) represents a promising area of research and medicine, which is witnessing tremendous technology advancements alongside the emergence of novel applications. The range of technologies associated with MD includes, amid others, gene expression profiling using microarrays, DNA probes, next-generation signal detection, first-generation amplification, fluorescent in-situ hybridization (FISH), second-generation microfluidics and biochips, and biosensors and molecular labels. These technologies are essential tools playing vital roles in the optimization of drug therapy, in the discovery of new therapeutic molecules for cancer as well as in the screening, classification and diagnosis of cancer patients. Presently, MD for cancer testing is deemed as the most lucrative area for innovations and growth.

The pool of MD industry players includes but is not limited to CombiMatrix Corporation, LabCorp, Rosetta Genomics, Biodesix, Nuvera Biosciences, Targeted Molecular Diagnostics, Exact Sciences Corporation, bioTheranostics, InterGenetics, Orion Genomics, Sequenom, SABiosciences Corporation, Cancer Genetics and Nuvera Biosciences.

In-demand research report “Molecular Diagnostics in Cancer Testing” drawn up by TriMark Publications LLC (TriMark) has been recently published by Market Publishers Ltd.

Report Details:

Title: Molecular Diagnostics in Cancer Testing
Published: November, 2013
Pages: 232
Price: US$ 3,400.00

The research study presents a comprehensive analysis of the MD field with a particular focus on the MD tests for cancer. It uncovers valuable information on the size and growth prospects of the MD market in its cancer detection and therapy applications; provides a thorough examination of the major factors influencing the development of the overall market and its certain segments, and also discloses sales statistics. The report presents description of the actual market state along with insights into the historical evolution of the sector, pinpoints the top market opportunities, covers the regulative framework, offers a snapshot of the existing MD technologies used for cancer testing applications as well as presents a summary of the recent business activities in the field. The study delves into the competitive landscape, unveils valuable data on the key market participants, and also contains forecasts for the MD market development in the next 5 years.

Report Features & Benefits:

  •     Extensive introduction to MD (insights into the historical background, a description of the current market landscape and a review of the market opportunities).
  •     Comprehensive analysis of the overall cancer diagnostics molecular testing market.
  •     Snapshot of the sales and marketing strategies.
  •     Examination of the competitive environment.
  •     Summary of the existing technologies used for cancer testing applications.
  •     Evaluation of the business environment, data on the recent business activities and SWOT comparison of business models.
  •     Characterization of the top market trends.
  •     Important information on the government regulations.
  •     Discussion of various business decisions using MD tests in cancer testing.
  •     Detailed company profiles.
  •     Five-year outlook for the MD market.

More insightful research reports by TriMark can be found at

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Coordinating the circadian clock: Molecular pair controls time-keeping and fat metabolism
2. Molecular probes identify changes in fibronectin that may lead to disease
3. Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor
4. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
5. Scientists discover distinct molecular subtype of prostate cancer
6. New molecular structure offers first picture of a protein family vital to human health
7. Grb2 holds powerful molecular signaling pathway in check
8. Better treatment for brain cancer revealed by new molecular insights
9. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
10. Researchers unveil molecular details of how bacteria propagate antibiotic resistance
11. Molecular switch identified that controls key cellular process
Post Your Comments:
(Date:11/28/2015)... ... , ... Safe storage for contraceptive devices may not always be easy to ... and the other from Bradley Beach, New Jersey, there is an easy solution to ... to replace NuvaRings more often than necessary. As such, it affords peace of mind ...
(Date:11/27/2015)... ... November 28, 2015 , ... There is only one major question facing ... last year? , This question has not been an easy question to answer. Especially ... age and the younger workforce don’t share the same discipline around working long hours. ...
(Date:11/27/2015)... ... 27, 2015 , ... The rapid speed at which Americans ... more care is needed, especially with Alzheimer’s, dementia and other cognitive conditions becoming ... The forgotten part of this equation: 80 percent of medical care occurs in ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... of progress through sharing, the 2016 Building Better Radiology Marketing Programs ... will begin on Sunday, March 6, 2016, at Caesars Palace in Las Vegas ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Italian therapeutic drug monitoring market, including emerging ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
(Date:11/25/2015)... Nov. 25, 2015  ARKRAY USA ... to provide evidence demonstrating the accuracy of its blood ... on Insulin Resistance, Diabetes and Cardiovascular Disease in ... the Company,s GLUCOCARD ® 01 meter and the ... requirements. The ability to accurately measure glucose levels in ...
Breaking Medicine Technology: